{"id":"purinostat-mesylate-for-injection","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Anorexia"},{"rate":"5-20%","effect":"Weight loss"},{"rate":"5-20%","effect":"Hypokalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This mechanism of action is thought to contribute to the induction of apoptosis and inhibition of cell proliferation in cancer cells. Histone deacetylase inhibitors like Purinostat Mesylate for Injection have been shown to have anti-tumor activity in various preclinical models.","oneSentence":"Purinostat Mesylate for Injection is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and changes in gene expression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:05.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory peripheral T-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT06485219","phase":"PHASE2","title":"A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2024-04-14","conditions":"Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)","enrollment":50},{"nctId":"NCT05563844","phase":"PHASE2","title":"Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2022-11-08","conditions":"Diffuse Large B Cell Lymphoma，DLBCL","enrollment":74},{"nctId":"NCT05526313","phase":"PHASE1","title":"Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant","status":"COMPLETED","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2020-08-10","conditions":"Diffuse Large B Cell Lymphoma，DLBCL","enrollment":29},{"nctId":"NCT07011056","phase":"PHASE3","title":"A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2025-07-18","conditions":"Recurrent and Refractory Diffuse Large B-cell Lymphoma","enrollment":390},{"nctId":"NCT06431243","phase":"PHASE1, PHASE2","title":"A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2024-05-08","conditions":"Advanced Solid Tumor","enrollment":132},{"nctId":"NCT06484829","phase":"PHASE1, PHASE2","title":"Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2024-03-25","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM)","enrollment":144}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Purinostat Mesylate for Injection","genericName":"Purinostat Mesylate for Injection","companyName":"Chengdu Zenitar Biomedical Technology Co., Ltd","companyId":"chengdu-zenitar-biomedical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Purinostat Mesylate for Injection is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and changes in gene expression. Used for Relapsed or refractory peripheral T-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}